Schedule a free discovery call

Conditions We Treat

  1. Home
  3. Conditions

Conditions

Care for depression, anxious depression and OCD

NeuroStar® TMS is FDA-cleared for the treatment of depression, anxious depression and obsessive-compulsive disorder (OCD), with options for adolescents and adults. It’s often considered when medication hasn’t been enough or isn’t the right fit.

Treatment-Resistant Depression

When antidepressants haven’t helped enough, have stopped working, or cause side effects you can’t tolerate. Learn more about NeuroStar® TMS for treatment-resistant depression.

Anxious Depression

Depression that comes with persistent worry, tension or restlessness.

Obsessive-Compulsive Disorder

Recurring, unwanted thoughts and repetitive behaviors that a person feels driven to perform.

TMS Greenwich patient with therapy dog during NeuroStar session
NeuroStar TMS treatment coil
Autumn lake reflection in Connecticut

Treatment-Resistant Depression

Learn More
Patient relaxing during NeuroStar TMS treatment with a clinician

NeuroStar® TMS Therapy

Learn More
Therapy dog resting by the TMS treatment chair

Medication Management

Learn More
Thunder and Carson, TMS Greenwich therapy dogs, resting together

Not sure where to start?

Find out if NeuroStar® TMS is right for you

Schedule a free, no-obligation discovery call, or start with our short online TMS self-assessment.

Schedule a free discovery call

Ready to feel like yourself again?

203.769.1365
Schedule a free discovery call
TMS Greenwich logo

Dedicated to helping you feel like you again with FDA-cleared NeuroStar® TMS Therapy in a calm, private Cos Cob office.

Quick Links

Services

Visit or Call

203.769.1365

GreenwichTMS@gmail.com

399 East Putnam Avenue, 2nd Floor, Suite 1, Cos Cob, CT 06807

Copyright © 2026 TMS Greenwich. All rights reserved. Individual results may vary.

Sources

  1. Mayberg HS, Liotti M, Brannan SK, et al. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry. 1999;156(5):675-682. PubMed 10327898 · doi:10.1176/ajp.156.5.675
  2. Koenigs M, Grafman J. The functional neuroanatomy of depression: distinct roles for ventromedial and dorsolateral prefrontal cortex. Behav Brain Res. 2009;201(2):239-243. PubMed 19428640 · doi:10.1016/j.bbr.2009.03.004
  3. Drevets WC, Price JL, Furey ML. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct. 2008;213(1-2):93-118. PubMed 18704495 · doi:10.1007/s00429-008-0189-x
  4. Liston C, Chen AC, Zebley BD, et al. Default mode network mechanisms of transcranial magnetic stimulation in depression. Biol Psychiatry. 2014;76(7):517-526. PubMed 24629537 · doi:10.1016/j.biopsych.2014.01.023
  5. Klomjai W, Katz R, Lackmy-Vallée A. Basic principles of transcranial magnetic stimulation (TMS) and repetitive TMS (rTMS). Ann Phys Rehabil Med. 2015;58(4):208-213. PubMed 26319963 · doi:10.1016/j.rehab.2015.05.005
  6. O’Reardon JP, Solvason HB, Janicak PG, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry. 2007;62(11):1208-1216. PubMed 17573044 · doi:10.1016/j.biopsych.2007.01.018
  7. Fox MD, Buckner RL, White MP, Greicius MD, Pascual-Leone A. Efficacy of transcranial magnetic stimulation targets for depression is related to intrinsic functional connectivity with the subgenual cingulate. Biol Psychiatry. 2012;72(7):595-603. PubMed 22658708 · doi:10.1016/j.biopsych.2012.04.028
  8. Philip NS, Barredo J, Aiken E, Carpenter LL. Neuroimaging mechanisms of therapeutic transcranial magnetic stimulation for major depressive disorder. Biol Psychiatry Cogn Neurosci Neuroimaging. 2018;3(3):211-222. PubMed 29486862 · doi:10.1016/j.bpsc.2017.10.007
  9. George MS, Lisanby SH, Avery D, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry. 2010;67(5):507-516. PubMed 20439832 · doi:10.1001/archgenpsychiatry.2010.46
  10. Carpenter LL, Janicak PG, Aaronson ST, et al. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depress Anxiety. 2012;29(7):587-596. PubMed 22689344 · doi:10.1002/da.21969
  11. Sackeim HA, Aaronson ST, Carpenter LL, et al. Clinical outcomes in a large registry of patients with major depressive disorder treated with Transcranial Magnetic Stimulation. J Affect Disord. 2020;277:65-74. PubMed 32799106 · doi:10.1016/j.jad.2020.08.005
  12. Neuronetics, Inc. NeuroStar clinical evidence (registry clinician-rated CGI-S outcomes and 12-month durability data). https://neurostar.com/hcp/evidence
  13. Dunner DL, Aaronson ST, Sackeim HA, et al. A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period. J Clin Psychiatry. 2014;75(12):1394-1401. PubMed 25271871 · doi:10.4088/JCP.13m08977
  14. Lefaucheur JP, Aleman A, Baeken C, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): an update (2014-2018). Clin Neurophysiol. 2020;131(2):474-528. PubMed 31901449 · doi:10.1016/j.clinph.2019.11.002

Sackeim 2020 (NeuroStar Outcomes Registry): 83% and 62% are clinician-rated CGI-S results, patient-rated rates were lower. Dunner 2014: 12-month follow-up with continued medication and TMS retreatment available. Individual results may vary.